RxDoctor Payments Data

Laurie Mortara, MD

Internal Medicine · Long Beach, CANPI 1932216124

Payments from drug & device makers

$160in general payments, 2019–2025

Across 8 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$62
  • Shionogi Inc$52
  • Johnson & Johnson$28
  • Gilead$13
  • Intra-sana Laboratories$4

What the payments were for

  • Food & beverage$13182%
  • Education$2818%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$160 in reported general payments places this provider in the 50th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$164,951
Medicare patients
454
Services billed
3,790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala272$1,232,643
GenvoyaElviteg/Cob/Emtri/Tenof Alafen38$246,817
IsentressRaltegravir Potassium57$112,581
JulucaDolutegravir/Rilpivirine20$70,100
EliquisApixaban93$64,637
DescovyEmtricitabine/Tenofov Alafenam25$51,012
StribildElviteg/Cob/Emtri/Tenofo Disop12$48,568
TivicayDolutegravir Sodium22$48,485
OzempicSemaglutide26$30,803
JardianceEmpagliflozin19$18,245
TrulicityDulaglutide19$16,888
RybelsusSemaglutide12$11,911
NamzaricMemantine Hcl/Donepezil Hcl28$3,977
ValacyclovirValacyclovir Hcl37$3,816
Levothyroxine Sodium334$3,810

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy, Stribild$13$1,579,040347 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →